knowledge -WSS

knowledge

author：entertainment 2025-09-06 02:15:28 - browse：799

Alex Hogan/STAT

SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan Healthcare Conference when we all collectively realized, “Oh, 2023 is going to be another slog.” Indeed, a downturn has weighed on the biotech industry for nearly three years.

But this January, things feel different. Maybe it’s the abundance of sunlight that filled San Francisco this week. More likely, it’s the surge of deals that came in December. Whatever the reason, sentiment around Union Square in recent days was markedly more positive this year.

Most everyone I spoke to this week noticed the change in tenor. “I’m feeling a lot of good energy, honestly,” Mira Chaurushiya, senior partner at VC Westlake Village BioPartners, told me Tuesday. “It’s not only what happened the last few weeks of the year, but what people are projecting moving forward.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： 'Patient friction coefficient' can gauge a clinical trial's patient burden

WSS

Biotech investment managers search for lucrative opportunities

Amylyx ALS drug failure raises questions and concerns

Pregnancy ages women, but effects reverse after delivery

Steward Health Care expansion into Malta flopped

Amylyx ALS drug failure raises questions and concerns

Readout Newsletter: Illumina, CRISPR, Regeneron

explore

knowledge

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Jerome Adams on the need for new antivirals for Covid

UnitedHealth quietly bought dozens of outpatient centers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What Kate Middleton's cancer revelation might teach the world

Hepatitis C has a cure — but many Americans still lack access to it

Just how do doctors, lawmakers, and the public define abortion?

Medicare proposal to cover medical devices draws a mixed reaction

How to bring more disabled researchers into academia

hotspot

Readout Newsletter: Illumina, CRISPR, Regeneron

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Erich Jarvis studies song birds to learn about human stuttering

CRISPR technology availability, affordability needs to be expanded

knowledge

hotspot

knowledge

focus